Preventability of venous thromboembolism in hospitalised patients

Intern Med J. 2023 Apr;53(4):577-583. doi: 10.1111/imj.15600. Epub 2022 Aug 13.

Abstract

Background: Hospital-acquired venous thromboembolism (VTE) is a major cause of morbidity and mortality.

Aims: To determine the proportion of patients with hospital-acquired VTE that are preventable.

Methods: This was a retrospective study of patients in two tertiary care hospitals in Sydney, Australia. Data were collected for patients with hospital-acquired VTE based on International Statistical Classification of Diseases and Related Health Problems, 10th Revision, Australian Modification (ICD-10-AM) coding from January 2018 to May 2020. Patients were classified as low, moderate or high risk of developing a VTE during hospitalisation based on demographic and clinical factors. A hospital-acquired VTE was considered to be potentially preventable if there was suboptimal prophylaxis in the absence of contraindications. Suboptimal therapy included at least one of the following related to VTE prophylaxis: low dose, missed dose (prior to developing a VTE), suboptimal drug and delayed start (>24 h from admission).

Results: There were 229 patients identified with VTE based on ICD-10-AM coding. A subset of 135 patients were determined to have actual hospital-acquired VTE. Of these, there were no patients at low risk, 64% (87/135) at moderate risk and 44% (48/135) at high risk of developing a VTE. Most (65%; n = 88/135) patients had one or more contraindications to receive recommended prophylaxis. Overall, the proportion of patients who received suboptimal prophylaxis was 11% (15/135).

Conclusion: Approximately one out of 10 hospital-acquired VTE are preventable. Hospitals should focus on measuring and reporting VTE that are preventable to provide a more accurate measure of the burden of VTE that can be reduced by improving care.

Keywords: deep vein thrombosis; hospital acquired; hospitalisation; pulmonary embolism; venous thromboembolism.

MeSH terms

  • Anticoagulants / therapeutic use
  • Australia / epidemiology
  • Hospitalization
  • Hospitals
  • Humans
  • Retrospective Studies
  • Risk Factors
  • Venous Thromboembolism* / drug therapy
  • Venous Thromboembolism* / epidemiology
  • Venous Thromboembolism* / prevention & control

Substances

  • Anticoagulants